HER2-Positive Breast Cancer Treatment
Is HER2-positive curable 2021?
With recent advances in medicine, it is considered that HER2-positive breast cancer is curable. With recent advances in medicine, it is considered that HER2-positive breast cancer is curable.
Can I survive HER2?
HER2-positive cancers are more aggressive than HER2-negative cancers. With treatment, however, the chances of survival are high, especially with an early diagnosis. In some cases, they may be higher than for HER2-negative breast cancer due to effective targeted treatment.
What is the survival rate of HER2-positive cancer?
The 4-year survival rates are as follows: HR+/HER2-: 92.5% HR+/HER2+: 90.3% HR-/HER2+: 82.7%
Is HER2-positive a death sentence?
Current treatment algorithms for invasive HER2-positive disease has transformed the face of a disease with a death sentence to one with prolonged and overall survival benefit.
Is chemo necessary for HER2-positive?
Trastuzumab and chemotherapy are even recommended for women with very small, HER2-positive breast cancers. Tumors as small as 0.5 cm often warrant such treatment. However, decisions must be individualized based on your own individual risk.
Is it better to be HER2-positive or negative?
Is HER2-positive breast cancer good or bad? HER2-positive cancer tends to be poorer in terms of prognosis than HER2-negative cancer because: It grows faster. It is more likely to spread to the lymph nodes fast.
Does HER2-negative require chemo?
Hormonal therapy is considered the standard initial treatment for HER2-negative metastatic breast cancer that is also hormone receptor-positive, and is often given in combination with targeted therapy. However, chemotherapy may also be given. A clinical trial may also be an option for treatment at any stage.
What is the most aggressive type of breast cancer?
Triple-negative breast cancer (TNBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.
What is the life expectancy of HER2-positive metastatic breast cancer?
With a median follow-up of 48 months, median OS and PFS were 63 months (CI95%, 50-71), and 18 months (CI95%, 15-21) respectively. In 111 patients (26.3%) classified as LTR, median OS was 110 months (CI95%, 95-not reached) versus 56 months in non-LTR patients (CI95%, 47-68).
Is HER2 cancer aggressive?
This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2 -positive breast cancers tend to be more aggressive than other types of breast cancer.